Skip to main content
70°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BioNTech SE
< Previous
1
2
Next >
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
October 19, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
October 16, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
October 16, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
September 28, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
September 18, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
August 30, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
August 14, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
August 07, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Completes Acquisition of InstaDeep
July 31, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
July 24, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
June 29, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 02, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
May 08, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
April 24, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
April 03, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces New ADS Repurchase Program
March 28, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
March 27, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
March 20, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
March 13, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
March 01, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
February 02, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
January 10, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
January 05, 2023
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 28, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
December 23, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
December 22, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Update on First BioNTainer for African-based mRNA Manufacturing Facility
December 21, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
December 21, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
December 09, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
BioNTech SE
Via
GlobeNewswire
Tickers
BNTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.